HomeKIMS › Filing
🔔 Get instant alerts when KIMS files quarterly results on BSE Start free trial →

Investor Presentation

Filed: 03 Aug 2026, 18:23 IST Exchange: NSE Category: Financial Results — Investor Presentation
Investor Presentation - Q1 FY27 - Total Revenue 11.96bn +36.1% y-y, EBITDA 2.40bn +20.1% y-y, PAT 374mn -56.0% y-y - Operational beds increased to 5,639 with occupancy at 49.0% - IP volume grew 26.6% y-y to 72,493; OP volume up 28.5% y-y to 658,617 - Telangana cluster leads revenue at 52.2% with 76.8% EBITDA contribution - Expansion includes 787 beds at Kondapur and 208 beds at Palakkad in Q1 FY27 - Advanced clinical programs and technology introduced across regions - Strategic doctor partnerships and regional market leadership drive growth - EBITDA margin at 20.1% on total revenue, slight QoQ improvement - Focus on affordable quality care with strong academic and research orientation
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 KIMS — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add KIMS to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on Krishna Institute of Medical Sciences Limited

Important. The summary above is generated automatically from Krishna Institute of Medical Sciences Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.